Altor BioScience Corporation In-Licenses Tissue Factor Antagonists from Genentech, Inc.
Published: Feb 12, 2008
MIRAMAR, Fla.--(BUSINESS WIRE)--Altor BioScience Corporation (Altor) announced today it has entered into an agreement with Genentech, Inc. for exclusive, worldwide rights to develop and commercialize a class of antibody-based Tissue Factor antagonists. Altor plans on initiating a multi-center, Phase II clinical study later this year, using the lead therapeutic antibody known as ALT-836 for the treatment of Acute Respiratory Distress Syndrome (ARDS) and Acute Lung Injury (ALI). Financial terms of the licensing transaction were not disclosed.